Developing Goal Directed Perfusion Therapy in SAH Neurocardiac Injury

开发 SAH 神经心脏损伤的目标定向灌注治疗

基本信息

项目摘要

DESCRIPTION: Up to 46% of patients surviving aneurysmal subarachnoid hemorrhage (aSAH) experience significant long- term disability. Emerging evidence suggests that post-aSAH myocardial injury (SAHMI), also called "neurocardiac injury" contributes to the development of secondary insult and therefore poorer outcomes. Improved ability to recognize and manage this complication could reduce the likelihood of adverse consequences. In prior work, we demonstrated that 31% of post-aSAH patients exhibit early elevated cardiac troponin I (cTnI) that is incrementally related to aSAH severity, and associated with myocardial regional wall motion abnormality (RWMA), depressed ejection fraction (EF), and dynamic cardiac arrhythmia that persists to some extent during hospitalization in over half of affected patients. We further determined that early elevated cTnI is associated with physical and neuropsychologic disability. We hypothesize that SAHMI blunts dynamic systemic and cerebral perfusion, producing a period of additive perfusion shortfall which contributes to poorer short and long term physical and neuropsychologic functional outcomes. Nurses are responsible for hemodynamic and neurologic monitoring of aSAH patients, but there are no evidence based recommendations driving clinical decisions for SAHMI perfusion support. We propose to utilize newer noninvasive macro and microcirculatory perfusion monitoring to determine SAHMI perfusion impact and develop perfusion supportive recommendations. Our study goal is to develop perfusion goal-directed therapeutic recommendations for SAHMI patients based upon the optimal perfusion parameters associated with better patient functional outcomes. We will determine the influence of SAHMI on dynamic systemic and cerebral perfusion, functional recovery, and SAHMI recovery trajectory. We will recruit 200 patients with aSAH (ages >21-75 years), and assess them for elevated cardiac troponin I, regional wall motion abnormalities and depressed ejection fraction on echocardiogram, and dynamic ectopy and arrhythmia via Holter monitoring. We will also utilize novel yet FDA-approved technologies to assess macro and microcirculatory perfusion impact. This will be accomplished with continuous noninvasive cardiac output monitoring (NICOM), peripheral microcirculatory (near-infrared spectroscopy [NIRS]), cerebral macro circulatory (cerebral perfusion pressure) and cerebral microcirculatory [cerebral NIRS]) perfusion monitoring in SAHMI and no-SAHMI subjects. We will also determine the impact SAHMI has on physical function as well as neuropsychologic function-a more sensitive measure of recovery and reintegration and therefore more reflective of the true burden imposed by SAHMI. We will then use this evidence to guide our development of clinically practicable perfusion goal-directed therapeutic recommendations. Analyses will include various regression modeling approaches as well as classification and regression trees. The application of targeted perfusion therapy at the bedside has the potential to improve outcomes and reduce aSAH burden on patients, the care system, and society.
描述:高达46%的动脉瘤性蛛网膜下腔出血(aSAH)患者存在严重的长期残疾。新出现的证据表明,asah后心肌损伤(SAHMI),也称为“神经心脏损伤”,有助于继发性损伤的发展,因此预后较差。提高识别和处理这种并发症的能力可以减少不良后果的可能性。在之前的研究中,我们证实了31%的aSAH后患者表现出早期心肌肌钙蛋白I (cTnI)升高,这与aSAH严重程度逐渐相关,并与心肌区域壁运动异常(RWMA)、射血分数下降(EF)和动态心律失常相关,超过一半的患者住院期间在一定程度上持续存在。我们进一步确定早期cTnI升高与身体和神经心理残疾有关。我们假设SAHMI使动态全身和脑灌注钝化,产生一段时间的灌注不足,从而导致较差的短期和长期身体和神经心理功能结果。护士负责aSAH患者的血流动力学和神经学监测,但没有基于证据的建议来推动临床决定SAHMI灌注支持。我们建议使用新的无创宏观和微循环灌注监测来确定SAHMI灌注影响并制定灌注支持建议。我们的研究目标是根据与更好的患者功能预后相关的最佳灌注参数,为SAHMI患者制定灌注目标导向的治疗建议。我们将确定SAHMI对动态全身和脑灌注、功能恢复和SAHMI恢复轨迹的影响。我们将招募200例aSAH患者(年龄21-75岁),并通过超声心动图评估其心肌肌钙蛋白I升高、局部壁运动异常和射血分数降低,以及动态异位和动态心电图监测心律失常。我们还将利用fda批准的新技术来评估宏观和微循环灌注影响。这将通过SAHMI和非SAHMI受试者的持续无创心输出量监测(NICOM)、外周微循环(近红外光谱[NIRS])、脑大循环(脑灌注压)和脑微循环[脑NIRS])灌注监测来完成。我们还将确定SAHMI对身体功能和神经心理功能的影响,这是一种更敏感的康复和重新融入社会的衡量标准,因此更能反映SAHMI带来的真正负担。然后,我们将使用这些证据来指导我们临床可行的灌注目标导向治疗建议的发展。分析将包括各种回归建模方法以及分类和回归树。在床边应用靶向灌注治疗有可能改善预后,减轻aSAH患者、护理系统和社会的负担。

项目成果

期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Vasopressor Infusion After Subarachnoid Hemorrhage Does Not Increase Regional Cerebral Tissue Oxygenation.
Clinical Presentation to the Emergency Department Predicts Subarachnoid Hemorrhage-Associated Myocardial Injury.
  • DOI:
    10.1016/j.jen.2017.06.005
  • 发表时间:
    2018-03
  • 期刊:
  • 影响因子:
    1.7
  • 作者:
    Yousef KM;Crago E;Lagattuta TF;Hravnak M
  • 通讯作者:
    Hravnak M
The Relationships Between BNP and Neurocardiac Injury Severity, Noninvasive Cardiac Output, and Outcomes After Aneurysmal Subarachnoid Hemorrhage.
  • DOI:
    10.1177/1099800417711584
  • 发表时间:
    2017-10
  • 期刊:
  • 影响因子:
    2.5
  • 作者:
    McAteer A;Hravnak M;Chang Y;Crago EA;Gallek MJ;Yousef KM
  • 通讯作者:
    Yousef KM
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Robert M. Friedlander其他文献

A Future Blood Test to Detect Cerebral Aneurysms
  • DOI:
    10.1007/s10571-023-01346-4
  • 发表时间:
    2023-04-12
  • 期刊:
  • 影响因子:
    4.800
  • 作者:
    Kamil W. Nowicki;Aditya M. Mittal;Hussam Abou-Al-Shaar;Emma K. Rochlin;Michael J. Lang;Bradley A. Gross;Robert M. Friedlander
  • 通讯作者:
    Robert M. Friedlander
ASSOCIATION OF GLOBAL LONGITUDINAL STRAIN WITH SEVERITY OF NEUROCARDIAC INJURY IN PATIENTS WITH SUBARACHNOID HEMORRHAGE
  • DOI:
    10.1016/s0735-1097(16)31611-4
  • 发表时间:
    2016-04-05
  • 期刊:
  • 影响因子:
  • 作者:
    Zhi Qi;Masataka Sugahara;Elizabeth A. Crago;Yuefang Chang;Theodore F. Lagattuta;Khalil Yousef;Robert M. Friedlander;Marilyn T. Hravnak;John Gorcsan
  • 通讯作者:
    John Gorcsan
NEUROCARDIAC INJURY IN PATIENTS WITH SUBARACHNOID HEMORRHAGE IS ASSOCIATED WITH REGIONAL LEFT VENTRICULAR DISCOORDINATION
  • DOI:
    10.1016/s0735-1097(16)31461-9
  • 发表时间:
    2016-04-05
  • 期刊:
  • 影响因子:
  • 作者:
    Zhi Qi;Masataka Sugahara;Elizabeth A. Crago;Yuefang Chang;Theodore F. Lagattuta;Khalil Yousef;Robert M. Friedlander;Marilyn T. Hravnak;John Gorcsan
  • 通讯作者:
    John Gorcsan
Utility of surveillance imaging for spontaneous intracerebral hemorrhage
  • DOI:
    10.1016/j.jocn.2019.08.011
  • 发表时间:
    2019-11-01
  • 期刊:
  • 影响因子:
  • 作者:
    Wi Jin Kim;Xiaoran Zhang;Nitin Agarwal;Bradley A. Gross;Aleksandra Safonova;Brian T. Jankowitz;Robert M. Friedlander
  • 通讯作者:
    Robert M. Friedlander
Solving Health Care's “Iron Triangle”: Neurosurgical Perspective
  • DOI:
    10.1016/j.wneu.2018.12.059
  • 发表时间:
    2019-03-01
  • 期刊:
  • 影响因子:
  • 作者:
    Prateek Agarwal;Nitin Agarwal;Robert M. Friedlander
  • 通讯作者:
    Robert M. Friedlander

Robert M. Friedlander的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Robert M. Friedlander', 18)}}的其他基金

Melatonin biosynthesis in neuronal mitochondria
神经元线粒体中褪黑激素的生物合成
  • 批准号:
    9444739
  • 财政年份:
    2018
  • 资助金额:
    $ 53.52万
  • 项目类别:
Melatonin biosynthesis in neuronal mitochondria
神经元线粒体中褪黑激素的生物合成
  • 批准号:
    9915981
  • 财政年份:
    2018
  • 资助金额:
    $ 53.52万
  • 项目类别:
Melatonin biosynthesis in neuronal mitochondria
神经元线粒体中褪黑激素的生物合成
  • 批准号:
    10382398
  • 财政年份:
    2018
  • 资助金额:
    $ 53.52万
  • 项目类别:
Developing Goal Directed Perfusion Therapy in SAH Neurocardiac Injury
开发 SAH 神经心脏损伤的目标定向灌注治疗
  • 批准号:
    9000020
  • 财政年份:
    2014
  • 资助金额:
    $ 53.52万
  • 项目类别:
Developing Goal Directed Perfusion Therapy in SAH Neurocardiac Injury
开发 SAH 神经心脏损伤的目标定向灌注治疗
  • 批准号:
    8629353
  • 财政年份:
    2014
  • 资助金额:
    $ 53.52万
  • 项目类别:
Developing Goal Directed Perfusion Therapy in SAH Neurocardiac Injury
开发 SAH 神经心脏损伤的目标定向灌注治疗
  • 批准号:
    8800577
  • 财政年份:
    2014
  • 资助金额:
    $ 53.52万
  • 项目类别:
Functional Role of Micro RNAs in Huntington's Disease Pathogenesis
Micro RNA 在亨廷顿病发病机制中的功能作用
  • 批准号:
    8807949
  • 财政年份:
    2012
  • 资助金额:
    $ 53.52万
  • 项目类别:
Functional Role of Micro RNAs in Huntington's Disease Pathogenesis
Micro RNA 在亨廷顿病发病机制中的功能作用
  • 批准号:
    8427325
  • 财政年份:
    2012
  • 资助金额:
    $ 53.52万
  • 项目类别:
Functional Role of Micro RNAs in Huntington's Disease Pathogenesis
Micro RNA 在亨廷顿病发病机制中的功能作用
  • 批准号:
    8616412
  • 财政年份:
    2012
  • 资助金额:
    $ 53.52万
  • 项目类别:
Functional Role of Micro RNAs in Huntington's Disease Pathogenesis
Micro RNA 在亨廷顿病发病机制中的功能作用
  • 批准号:
    8319931
  • 财政年份:
    2012
  • 资助金额:
    $ 53.52万
  • 项目类别:

相似国自然基金

靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
  • 批准号:
    JCZRQN202500010
  • 批准年份:
    2025
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
  • 批准号:
    2025JJ70209
  • 批准年份:
    2025
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
  • 批准号:
  • 批准年份:
    2024
  • 资助金额:
    0 万元
  • 项目类别:
    面上项目
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
  • 批准号:
    2023JJ50274
  • 批准年份:
    2023
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
  • 批准号:
  • 批准年份:
    2022
  • 资助金额:
    33 万元
  • 项目类别:
    地区科学基金项目
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
  • 批准号:
    n/a
  • 批准年份:
    2022
  • 资助金额:
    10.0 万元
  • 项目类别:
    省市级项目
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
  • 批准号:
    81973577
  • 批准年份:
    2019
  • 资助金额:
    55.0 万元
  • 项目类别:
    面上项目
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
  • 批准号:
    81602908
  • 批准年份:
    2016
  • 资助金额:
    18.0 万元
  • 项目类别:
    青年科学基金项目
高血糖激活滑膜AGE-RAGE-PKC轴致骨关节炎易感的机制研究
  • 批准号:
    81501928
  • 批准年份:
    2015
  • 资助金额:
    18.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

PROTEMO: Emotional Dynamics Of Protective Policies In An Age Of Insecurity
PROTEMO:不安全时代保护政​​策的情绪动态
  • 批准号:
    10108433
  • 财政年份:
    2024
  • 资助金额:
    $ 53.52万
  • 项目类别:
    EU-Funded
The role of dietary and blood proteins in the prevention and development of major age-related diseases
膳食和血液蛋白在预防和发展主要与年龄相关的疾病中的作用
  • 批准号:
    MR/X032809/1
  • 财政年份:
    2024
  • 资助金额:
    $ 53.52万
  • 项目类别:
    Fellowship
Atomic Anxiety in the New Nuclear Age: How Can Arms Control and Disarmament Reduce the Risk of Nuclear War?
新核时代的原子焦虑:军控与裁军如何降低核战争风险?
  • 批准号:
    MR/X034690/1
  • 财政年份:
    2024
  • 资助金额:
    $ 53.52万
  • 项目类别:
    Fellowship
Collaborative Research: Resolving the LGM ventilation age conundrum: New radiocarbon records from high sedimentation rate sites in the deep western Pacific
合作研究:解决LGM通风年龄难题:西太平洋深部高沉降率地点的新放射性碳记录
  • 批准号:
    2341426
  • 财政年份:
    2024
  • 资助金额:
    $ 53.52万
  • 项目类别:
    Continuing Grant
Collaborative Research: Resolving the LGM ventilation age conundrum: New radiocarbon records from high sedimentation rate sites in the deep western Pacific
合作研究:解决LGM通风年龄难题:西太平洋深部高沉降率地点的新放射性碳记录
  • 批准号:
    2341424
  • 财政年份:
    2024
  • 资助金额:
    $ 53.52万
  • 项目类别:
    Continuing Grant
Doctoral Dissertation Research: Effects of age of acquisition in emerging sign languages
博士论文研究:新兴手语习得年龄的影响
  • 批准号:
    2335955
  • 财政年份:
    2024
  • 资助金额:
    $ 53.52万
  • 项目类别:
    Standard Grant
The economics of (mis)information in the age of social media
社交媒体时代(错误)信息的经济学
  • 批准号:
    DP240103257
  • 财政年份:
    2024
  • 资助金额:
    $ 53.52万
  • 项目类别:
    Discovery Projects
How age & sex impact the transcriptional control of mammalian muscle growth
你多大
  • 批准号:
    DP240100408
  • 财政年份:
    2024
  • 资助金额:
    $ 53.52万
  • 项目类别:
    Discovery Projects
Supporting teachers and teaching in the age of Artificial Intelligence
支持人工智能时代的教师和教学
  • 批准号:
    DP240100111
  • 财政年份:
    2024
  • 资助金额:
    $ 53.52万
  • 项目类别:
    Discovery Projects
Enhancing Wahkohtowin (Kinship beyond the immediate family) Community-based models of care to reach and support Indigenous and racialized women of reproductive age and pregnant women in Canada for the prevention of congenital syphilis
加强 Wahkohtowin(直系亲属以外的亲属关系)以社区为基础的护理模式,以接触和支持加拿大的土著和种族育龄妇女以及孕妇,预防先天梅毒
  • 批准号:
    502786
  • 财政年份:
    2024
  • 资助金额:
    $ 53.52万
  • 项目类别:
    Directed Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了